BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsConference / presentation

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21 st Annual Healthcare Conference on Tuesday, September 8 th H.C.

Related news

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-05-06 20:05 EST

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

OKYOOKYO Pharma2026-09-08 11:00 EST

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

BLTEBelite Bio2026-06-02 12:00 EST

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

SGHTSight Sciences2026-09-01 20:05 EST

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

OTLKOutlook2026-08-27 13:01 EST

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

PRQRProQR Therapeutics2026-05-11 12:00 EST

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

OKYOOKYO Pharma2026-07-27 11:00 EST

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

BLTEBelite Bio2026-07-15 12:00 EST

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-09-04 12:39 EST

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

TARSTarsus Pharmaceuticals2026-09-01 20:30 EST

Tarsus to Participate in Upcoming Investor Conferences

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

TARSTarsus Pharmaceuticals2026-08-06 11:01 EST

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Stock data

Close
79.03 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States